ArticlePostepy dermatologii i alergologii2021
Sublingual immunotherapy in mite-sensitized patients with atopic dermatitis: a randomized controlled study.
Article in Postepy dermatologii i alergologii, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- Effect of house dust mite sublingual immunotherapy in patients with adult atopic dermatitis with rhinitis.Future science OA · 2024Article
- Advancements in Allergen Immunotherapy for the Treatment of Atopic Dermatitis.International journal of molecular sciences · 2024Review
- KAAACI Guidelines for Allergen Immunotherapy.Allergy, asthma & immunology research · 2023Review
- A concept for integrated care pathways for atopic dermatitis-A GAClinical and translational allergy · 2023Review
- Is there room for allergen immunotherapy for the treatment of atopic dermatitis in the precision medicine era?Frontiers in pediatrics · 2022Article
- [Allergen immunotherapy for atopic dermatitis].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSublingual immunotherapy (SLIT) has been shown to be efficacious in patients with airway allergic diseases. However, less data have been demonstrated to show the efficacy of SLIT in patients with atopic dermatitis (AD).
aimThis study is to evaluate, in a randomized controlled study, the effect of SLIT with house dust mite (HDM) in patients with mild-moderate AD. MATERIAL AND
methodsAD patients aged 4 to 60 years with a Scoring Atopic Dermatitis (SCORAD) score of 7-40 and sensitization to HDM were enrolled in the study. SLIT or control treatment was given for 24 months. SCORAD, visual analog scale (VAS) score were recorded at 6, 12, 24 month, and rescue medications were required to be recorded in the diary card. A serum level of specific IgE was tested at 24-month treatment.
resultsNinety-six patients were enrolled, and forty-eight were allocated to SLIT. Thirty-nine patients in the SLIT group and thirty-eight patients in the control group completed the study. The patients in the SLIT group had significantly decreased ΔSCORAD, VAS and rescue medication score from 12 months' treatment compared with the control group (
conclusionsTwo years' SLIT to HDM significantly improved the clinical symptoms and reduced drug use in patients with mild-moderate AD. SLIT may represent an additional therapeutic tool for the treatment of AD in properly selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.